Avanir Pharmaceuticals recently received an approvable letter from the FDA regarding its lead product candidate for the treatment of involuntary emotional expression disorder, Zenvia. While that doesn't mean the drug is approved for marketing in the United States at this time, Avanir President and CEO Eric Brandt is optimistic about its outlook.
If approved, Avanir would have the first drug of its kind on the market, with an estimated patient population of 1 million people. It also would be the first time Avanir would promote and sell a drug it developed, rather than licensing the drug out to marketing partners.
Yet Zenvia is just one of several moving parts in a changing company. Avanir is consolidating its San Diego offices and laboratory space into one building, with plans to keep research and development here, but move office support and commercial activities to a new headquarters facility in Orange County.